This trial was designed to evaluate the efficacy and safety of SHR-1819 injection in patients with Prurigo Nodularis.
Subjects voluntarily sign informed consent forms prior to the commencement of any proceedings related to the study, are able to communicate smoothly with the investigator, understand and are willing to complete the study in strict compliance with the requirements of this clinical research protocol.
The age was ≥18 at the time of signing the informed consent and gender is unlimited.
Has prurigo nodularis at screening.
Pregnant or lactating women.
Screening for people with a history of heavy alcohol consumption or substance abuse in the 6 months prior to screening.
Has an active skin disease or skin complications due to other diseases that may affect the evaluation of PN.
PN secondary to medical conditions such as neurological or psychiatric disorders.